Loading clinical trials...
Loading clinical trials...
A Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
Conditions
Interventions
BYL719
Fulvestrant
Locations
11
United States
UCSF Medical Center
San Francisco, California, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(4)
Nashville, Tennessee, United States
Vanderbilt Univeristy SC
Nashville, Tennessee, United States
MD Anderson Cancer Center/University of Texas MD Anderson
Houston, Texas, United States
Novartis Investigative Site
Essen, Germany
Start Date
October 5, 2010
Primary Completion Date
February 5, 2015
Completion Date
April 16, 2020
Last Updated
September 22, 2020
NCT01984138
NCT01992952
NCT01996046
NCT00066690
NCT02409316
NCT04727632
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions